ADMA Biologics Increases FY24 Revenue Exceeds $290M Vs $278.4M Est.
Portfolio Pulse from Benzinga Newsdesk
ADMA Biologics has increased its FY24 revenue forecast to exceed $290 million, up from the previous estimate of $278.4 million.
November 08, 2023 | 10:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics has raised its FY24 revenue forecast, which could positively impact investor sentiment and potentially the stock price.
ADMA Biologics has increased its FY24 revenue forecast, which is a positive signal for investors. This could lead to increased investor confidence in the company's future performance, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100